Nerites Corporation Names Shaun Lonergan as Chief Executive Officer

Thu. March 05, 2009; Posted: 10:18 AM

MADISON, Wis., Mar 05, 2009 (BUSINESS WIRE) -- TWTI | Quote | Chart | News | PowerRating -- Shaun C. Lonergan joins Nerites Corporation as Chief Executive Officer and member of the Board of Directors with a distinguished record of success in building medical technology companies that leverage corporate partners to launch innovative products. Most recently, Mr. Lonergan served as Vice President of Sales, Marketing, and Business Development for Ibis Biosciences, leading to its sale for $215 Million to Abbott Molecular in January, 2009. Prior to Ibis, Mr. Lonergan held similar executive positions at 454 Life Sciences, where he closed a $62 Million distribution agreement with Roche Diagnostics, and NimbleGen Systems, which was acquired by Roche Diagnostics for $273 Million in 2007. Earlier in his career, Mr. Lonergan was Vice President of Corporate Development at Third Wave Technologies, where he participated in completing an Initial Public Offering valuing the company at $325 Million.

"Since founding Nerites in 2004, I have looked forward to the day when the market validates our vision to the point that we can attract executives of Shaun's caliber," stated former CEO Thomas Mozer, who will continue to serve as President and Chief Operations Officer. "Our technology is maturing and we've made headway in product development. The Nerites team welcomes Shaun and we're all very excited about the opportunities that his leadership will present."

George Arida, Chairman of the Nerites Board of Directors, commented: "We're extremely pleased to welcome Shaun Lonergan as Nerites' new CEO. Shaun has broad and deep experience in commercializing new technologies and driving growth. Bringing Shaun on board will drive future partnerships and position us well for upcoming clinical trials and product commercialization."

"Nerites has a solid foundation with an extremely innovative platform technology," stated Lonergan. "They have attracted early partners and established a strong product pipeline. My goal in joining Nerites is to accelerate the commercial development process and broaden our set of corporate relationships. Many of the pieces are in place for an immensely successful medical device firm."

About Nerites: Nerites Corporation commercializes, through partners, a new generation of synthetic bio-adhesives that can enhance natural tissue repair, reduce postoperative complications, and degrade safely when they are no longer needed. The hydrogel technology can be used to close internal tears or incisions, to prevent leakage and infection, and to affix synthetic or biologic medical devices. Properties can be "tuned" to fit each application. The technology was described with a cover article in the journal Nature (July, 2007) and was labeled "one of the top 100 scientific developments of 2007" by Discover Magazine. (www.Nerites.com)

SOURCE: Nerites Corporation

Nerites Corporation 
Jediah White 
Director of Business Development 
525 Science Drive Suite 215 
Madison, WI 53711 
847-727-1747 
jwhite@nerites.com

For full details for TWTI click here.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index

Archives

Feedback

Email Article Link

Close X

RELATED SITES

Please call 1-213-955-5858 ext. 1

Tax Relief Bank Levy Wage Garnishment

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.